Article Text

Download PDFPDF
Switching to aripiprazole from olanzapine leads to weight loss in overweight people with schizophrenia or schizoaffective disorder

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Source of funding: Bristol-Myers Squibb (Princeton, NJ, USA) and Otsuka Pharmaceuticals Co Ltd (Tokyo, Japan).


  • Competing interests: TJRL has received research funds and been on advisory boards and speaker bureaus for both Eli Lilly (olanzapine) and BMS (aripiprazole).